No abstract available.
Drug Therapy* ; Erectile Dysfunction* ; Male

Erectile dysfunction (ED) affects over 50% of men between 50 and 70 years of age, and 40% of men aged about 40 years suffer from some form of erectile dysfunction. ED, with more than 100 million sufferers in the world, has become a serious disease besetting the male patients. Great strides have been achieved in understanding the pathogenesis and potential therapeutics of ED over the past two decades. The development of phosphodiesterase type 5 (PDE5) inhibitors has revolutionized the treatment of ED, but they are not as effective on ED related with diabetes, post-prostatectomy condition and severe veno-occlusive disease. As a potential therapeutic option for ED, gene therapy might provide an effective means. This article presents an overview on the progress of gene therapy in the management of ED associated with diabetes, aging, nerve injury and vascular lesion.
Erectile Dysfunction ; therapy ; Genetic Therapy ; Humans ; Male

Erectile dysfunction (ED) is a major sexual dysfunction involving both physiological and psychological factors. While the primary physiological cause of ED is associated with endocellular degeneration and disorders of neural reflex, its psychological causes are mainly hyposexuality, anxiety and depression. Increasing importance is being attached to the psychological aspects in the diagnosis and management of ED in recent years, and the evaluation questionnaires aimed at the psychosocial significance in ED patients' conditions and psychological interventions solo or combined with drugs have inspired many researches for an optimal solution of the disease. Improvement of the patient's erectile performance is no longer the only outcome we pursue. Instead, the satisfaction of both the patient and his partner has a rising weight in the final evaluation of a therapy. The wide application of PED5 inhibitors and their psychological effect on ED patients makes it necessary for us gain a deeper insight into the combination of psychological intervention and drug therapy in the management of ED.
Erectile Dysfunction ; diagnosis ; psychology ; therapy ; Humans ; Male

Sexual dysfunction is common among male adults. Here we summarized the recent papers and provided the outline of diagnosis and treatment on male sexual dysfunction.
Adult ; Erectile Dysfunction ; diagnosis ; therapy ; Humans ; Male

The incidence of erectile dysfunction (ED) rises with the increase of age, for which gene therapy is a new option in the recent years. Different target genes, vehicles and therapeutic strategies have been tried and yielded good results. This paper offers an overview of the current advances in gene therapy for aging-related ED.
Aging ; Animals ; Erectile Dysfunction ; therapy ; Genetic Therapy ; Male ; Rats

Acupuncture Therapy ; Adult ; Erectile Dysfunction ; therapy ; Humans ; Male

PURPOSE: To compare the efficacy of Bimix solution (27.3 mg/ml papaverine and 0.9 mg/ml phentolamine) versus Trimix solution (18.8 mg/ml papaverine, 0.6 mg/ml phentolamine and 6.3ug/ml prostaglandin El) in terms of erectile response and complications. MATERIALS AND METHODS: We comparatively analyzed the erectile response and the incidence of pain, prolonged erection (>4 hours), and corporal fibrosis of either medication in the 155 impotent patients who used Bimix solution for intracavernous pharmacotherapy (mean duration: 15 months) and thereafter used Trimix solution (mean 12 months). RESULTS: Erectile response to Trimix solution was significantly better than Bimix solution (p<0.01). The mean dose of Bimix solution was higher than Trimix solution (0.43 ml. vs. 0.34 ml, p<0.05). The severe pain enough for impediment to ntercourse occurred in 6.5% of the Trimix group, while no patient of the Bimix group experienced (p<0.01). The corporal fibrosis was noted in 8.4% of the Trimix group and 16.1% of the Bimix group. However, there was no significant difference between the two groups (p=0.08). The incidence of prolonged erection was significantly lower (p<0.05) in the Trimix group (2.6%) than in the Bimix group (12.3%). A total of 139 patients (89.7%) finally selected Trimix solution. CONCLUSIONS: The Trimix solution was more effective and safer than Bimix solution for the treatment of erectile dysfunction.
Drug Therapy ; Erectile Dysfunction* ; Fibrosis ; Humans ; Incidence ; Male ; Papaverine ; Phentolamine

Erectile dysfunction (ED) is a common male sexual dysfunction. Some ED patients who do not respond to any nonsurgical therapy will eventually be candidate for penile prostheses. This paper introduces the characteristics and application of inflatable penile prosthesis made in China.
Erectile Dysfunction ; therapy ; Humans ; Male ; Penile Prosthesis ; Prosthesis Design

Patients with chronic renal failure (CRF) experience a significant decrease in their living quality, due to the limitations imposed by the disease as well as the demands of the treatment that they receive. Some side effects contribute to the morbidity of these patients. Among them, erectile dysfunction (ED) is notable. This article reviews recent advances in etiological factor study and treatment of ED in CRF patients, which may guide the clinic practices in a considerable scale.
Erectile Dysfunction ; etiology ; therapy ; Humans ; Kidney Failure, Chronic ; complications ; Male

There has been remarkable progress in the treatment of erectile dysfunction during last decade. We have analyzed 2,000 patients with erectile dysfunction who had been treated with a variety of treatment modalities during last 10 years to identify the annual changes in the proportion of the respective treatment modality. The most remarkable change was seen in the proportion of patients treated by vasoactive pharmacotherapy The proportion was 12.0% on 1984, which was gradually increased in time, and reached to 82.1% on 1994. Another remarkable change was found in the proportion of patients treated by surgery, especially vascular surgery : The proportion of patients treated by penile prosthesis implantation on 1985 and vein ligation on 1986 was 64.0% and 14.3%, respectively ; whereas, it was decreased to 1.8 % and 0% on 1994, respectively. In conclusion, we could find remarkable change of trend in the primary treatment modality for erectile dysfunction from invasive and costly surgical treatment to less invasive and cheap vasoactive pharmacotherapy. Nowadays, intracavernous self-injection of vasoactive agents plays a primary role in the treatment of impotence. Penile prosthesis implantation remains as the last treatment modality for erectile dysfunction. However, vascular surgery is rarely being performed nowadays because of its poor long-term outcome.
Drug Therapy ; Erectile Dysfunction* ; Humans ; Ligation ; Male ; Penile Implantation ; Veins